BioSpace News Archive

Sagimet Biosciences Inc. announces the acceptance of two abstracts, one of which is a late-breaking poster, at the American Association for the Study of Liver Diseases – The Liver Meeting® 2023, to be held November 10-14, 2023 in Boston, MA.

Araclon Biotech, a Grifols Group company dedicated to the research and development of therapies and diagnostic methods applied to neurodegenerative diseases, today announced encouraging final results from its Phase 2 trial (NCT03461276) of ABvac40, an active vaccine against the Aβ40 peptide, for the treatment of patients with early-stage Alzheimer’s disease (AD).

Coherus BioSciences, Inc., announced that effective October 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 64,500 shares of the common stock of the Company to eight newly hired employees with a per share exercise price of $3.54, the closing trading price on the grant date.

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants.

GE HealthCare has topped a U.S. Food and Drug Administration list of artificial intelligence enabled medical devices with 58 listed 510 clearances or authorizations to date in the United States.

Rancho Biosciences, the premier Data Science Services company headquartered in San Diego, California, is thrilled to extend a warm invitation to LLM enthusiasts, experts, and professionals in the Life Sciences sector.

Biostax Corp, a leading public company specializing in healthcare solutions, announced a milestone in its transformative rebranding initiative.

ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, today announced the first patient treated in its Route90 US IDE Pivotal study.

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark”) a leading liquid biopsy company focusing on metabolomics for the early diagnosis of hard to detect and treat cancers

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced today that the company will be presenting 16 posters and exhibiting at booth 223 at the Society for Immunotherapy of Cancer (SITC) annual conference, taking place from November 1-5, 2023 in San Diego, CA.